SCHEMBL1198028

SCHEMBL1198028

O=C(O)c1cnn(-c2nc(-c3ccc(Cl)s3)cs2)c1C(F)(F)F

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.73
KMT2A Q03164 7/20 0.73
RAB9A P51151 4/20 0.73
NPC1 O15118 3/20 0.73
CRHBP P24387 1/20 0.69
MC4R P32245 1/20 0.69
CRHR2 Q13324 1/20 0.69
KDM4E B2RXH2 7/20 0.68
ALDH1A1 P00352 4/20 0.64
ATM Q13315 1/20 0.63
HPGD P15428 5/20 0.53
L3MBTL1 Q9Y468 4/20 0.53
MAPT P10636 3/20 0.53
GAA P10253 2/20 0.53
TDP1 Q9NUW8 1/20 0.53
CYP1A2 P05177 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
POLB P06746 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1198087 0.85 KDM4E (0.73) MEN1KMT2ARAB9ANPC1CRHBP
SCHEMBL1199346 0.84 KDM4E (0.68) MEN1KMT2ARAB9ANPC1CRHBP
SCHEMBL1198727 0.84 MEN1 (1.00) MEN1KMT2ARAB9ANPC1CRHBP
SCHEMBL12875525 0.84 MEN1 (0.52) MEN1KMT2ARAB9ANPC1CRHBP
SCHEMBL1198638 0.83 KDM4E (0.83) MEN1KMT2ARAB9ANPC1CRHBP
SCHEMBL1197544 0.82 MEN1 (1.00) MEN1KMT2ARAB9ANPC1CRHBP
SCHEMBL1198885 0.81 KDM4E (0.81) MEN1KMT2ARAB9ANPC1CRHBP
SCHEMBL1198401 0.81 KDM4E (1.00) MEN1KMT2ARAB9ANPC1CRHBP
SCHEMBL4829071 0.81 KDM4E (0.72) MEN1KMT2ARAB9ANPC1CRHBP
SCHEMBL4829271 0.81 KDM4E (0.83) MEN1KMT2ARAB9ANPC1CRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
CN-102056907-A Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL 2011-05-11 CN disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A MEN1 2661/4885KMT2A 3197/4885RAB9A 2507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.